Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 27733634)

Published in J Clin Microbiol on October 12, 2016

Authors

A Jayakumar¹, R M Savic², C K Everett¹, D Benator³, D Alland⁴, C M Heilig⁵, M Weiner⁶, S O Friedrich⁷, N A Martinson⁸, A Kerrigan⁹, C Zamudio¹⁰, S V Goldberg⁵, W C Whitworth⁵, J L Davis¹¹, P Nahid¹²

Author Affiliations

1: University of California, San Francisco, Division of Pulmonary and Critical Care Medicine, San Francisco, California, USA.
2: University of California, San Francisco, School of Pharmacy, San Francisco, California, USA.
3: Washington DC VA Medical Center and the George Washington University, Washington, DC, USA.
4: Rutgers-New Jersey Medical School, Newark, New Jersey, USA.
5: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
6: Veterans Administration Medical Center and University of Texas Health Science Center, San Antonio, Texas, USA.
7: Division of Medical Physiology, MRC Centre for Tuberculosis Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
8: Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Centre for HIV/AIDS and TB, University of the Witwatersrand, Johannesburg, South Africa.
9: Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
10: Universidad Peruana Cayetano Heredia, Lima, Peru.
11: Yale School of Public Health, New Haven, Connecticut, USA.
12: University of California, San Francisco, Division of Pulmonary and Critical Care Medicine, San Francisco, California, USA pnahid@ucsf.edu.

Articles cited by this ↗

Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol (2010) 7.90

Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn (2001) 6.00

Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis (1993) 3.01

Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis (2010) 2.61

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med (2013) 2.28

Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLoS Med (2014) 2.05

Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis (2013) 2.05

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86

A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am J Respir Crit Care Med (2011) 1.66

Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med (2014) 1.49

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med (2011) 1.37

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis (2016) 1.33

GeneXpert MTB/RIF version G4 for identification of rifampin-resistant tuberculosis in a programmatic setting. J Clin Microbiol (2013) 1.28

How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries? Eur Respir J (2014) 1.09

Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB. PLoS One (2016) 0.84

Articles by these authors ⇆

Factors associated with recurrent tuberculosis more than 12 months after treatment completion. Int J Tuberc Lung Dis (2016) 1.44